One-Hour Low-Cost Multipurpose Highly Efficient System (HOLMES) Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Diagnostics Market Report 2026

The one-hour low-cost multipurpose highly efficient system (holmes) clustered regularly interspaced short palindromic repeats (crispr) diagnostics market size has grown exponentially in recent years. It will grow from $1.49 billion in 2025 to $1.79 billion in 2026 at a compound annual growth rate (CAGR) of 20.1%. The growth in the historic period can be attributed to growth in molecular diagnostics, expansion of crispr research, rise in infectious disease testing, increase in rapid test demand, genomics technology advances.

The one-hour low-cost multipurpose highly efficient system (holmes) clustered regularly interspaced short palindromic repeats (crispr) diagnostics market size is expected to see exponential growth in the next few years. It will grow to $3.75 billion in 2030 at a compound annual growth rate (CAGR) of 20.4%. The growth in the forecast period can be attributed to expansion of point of care molecular testing, rising demand for rapid pathogen detection, growth in personalized diagnostics, increased crispr clinical adoption, broader field deployable testing. Major trends in the forecast period include rapid crispr based diagnostic assays, point of care crispr testing kits, multiplex gene detection panels, portable molecular crispr platforms, low cost nucleic acid detection kits.

The increasing prevalence of infectious diseases is anticipated to drive the expansion of the hybrid oligonucleotide linked modular enzyme system (HOLMES) clustered regularly interspaced short palindromic repeats (CRISPR) diagnostics market in the future. Infectious diseases are illnesses caused by the invasion of harmful microorganisms into the body, which can spread through contact, air, water, or vectors. The incidence of infectious diseases is rising due to urbanization and high population density, which facilitate faster transmission of pathogens. HOLMES CRISPR Diagnostics assists in detecting infectious diseases by employing CRISPR-Cas enzymes to rapidly and accurately identify specific genetic sequences of pathogens, enabling fast, sensitive, and point-of-care diagnosis. For example, in February 2024, according to GOV.UK, a UK government department, tuberculosis (TB) cases in England increased by 10.7% in 2023, rising from 4,380 in 2022 to 4,850. Therefore, the increasing prevalence of infectious diseases is propelling the growth of the hybrid oligonucleotide linked modular enzyme system (HOLMES) clustered regularly interspaced short palindromic repeats (CRISPR) diagnostics market.

The growing adoption of precision medicine is expected to drive the expansion of the hybrid oligonucleotide linked modular enzyme system (HOLMES) clustered regularly interspaced short palindromic repeats (CRISPR) diagnostics market going forward. Precision medicine entails delivering personalized healthcare by accounting for an individual’s genetic, environmental, and lifestyle factors. Its adoption is rising due to advances in genomics, which allow healthcare professionals to identify genetic variations and develop targeted therapies, improving patient outcomes. The HOLMES CRISPR diagnostics system supports precision medicine by quickly and accurately detecting specific genetic mutations or pathogens in a patient’s DNA or RNA, enabling customized treatments and early interventions based on a person’s unique genetic profile. For example, in February 2024, according to the Personalized Medicine Coalition, a US non-profit organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. The newly approved treatments for 2023 also include seven cancer therapies and three for other conditions. Therefore, the growing adoption of precision medicine is driving the expansion of the hybrid oligonucleotide-linked modular enzyme system (HOLMES) clustered regularly interspaced short palindromic repeats (CRISPR) diagnostics market.

The increasing healthcare expenditure is anticipated to propel the growth of the hybrid oligonucleotide linked modular enzyme system (HOLMES) clustered regularly interspaced short palindromic repeats (CRISPR) diagnostics market going forward. Healthcare expenditure refers to the financial resources used for prevention, diagnosis, treatment, and management of illnesses and health conditions. Spending on healthcare is rising due to the growing prevalence of chronic diseases, which require continuous treatment and medical care. Higher healthcare investment supports the use of HOLMES CRISPR diagnostics by funding advanced testing technologies and enhancing diagnostic accessibility. For example, in December 2024, according to the Centers for Medicare & Medicaid Services, a US agency overseeing Medicare and Medicaid, U.S. healthcare expenditures increased by 7.5% in 2023, reaching $4.9 trillion, or approximately $14,570 per individual. Therefore, the increasing healthcare expenditure is driving the growth of the hybrid oligonucleotide linked modular enzyme system (HOLMES) clustered regularly interspaced short palindromic repeats (CRISPR) diagnostics market.

Major companies operating in the one-hour low-cost multipurpose highly efficient system (holmes) clustered regularly interspaced short palindromic repeats (crispr) diagnostics market are Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Agilent Technologies Inc., Bio‑Rad Laboratories Inc., Qiagen N.V., Integrated DNA Technologies Inc., GenScript Biotech Corporation, OraSure Technologies Inc., Molbio Diagnostics Pvt. Ltd., New England Biolabs Inc., Horizon Discovery Group plc, Mammoth Biosciences, Synthego Corporation, Binx Health Inc., Sherlock Biosciences Inc., Caspr Biotech, Tolo Biotechnology Co. Ltd., CrisprBits Private Limited, Scope Biosciences.

Tariffs on diagnostic reagents, enzymes, and microfluidic components are raising production costs in the holmes crispr diagnostics market. Kit and reagent segments that depend on imported biochemical inputs are most affected. Diagnostic manufacturers in import reliant regions face higher consumable pricing. These increases can impact affordability of rapid molecular tests in smaller labs. At the same time, tariffs are supporting local reagent production and regional diagnostic kit manufacturing capacity.

The one-hour low-cost multipurpose highly efficient system (holmes) clustered regularly interspaced short palindromic repeats (crispr) diagnostics market research report is one of a series of new reports that provides one-hour low-cost multipurpose highly efficient system (holmes) clustered regularly interspaced short palindromic repeats (crispr) diagnostics market statistics, including one-hour low-cost multipurpose highly efficient system (holmes) clustered regularly interspaced short palindromic repeats (crispr) diagnostics industry global market size, regional shares, competitors with a one-hour low-cost multipurpose highly efficient system (holmes) clustered regularly interspaced short palindromic repeats (crispr) diagnostics market share, detailed one-hour low-cost multipurpose highly efficient system (holmes) clustered regularly interspaced short palindromic repeats (crispr) diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the one-hour low-cost multipurpose highly efficient system (holmes) clustered regularly interspaced short palindromic repeats (crispr) diagnostics industry. This one-hour low-cost multipurpose highly efficient system (holmes) clustered regularly interspaced short palindromic repeats (crispr) diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

One-hour Low-cost multipurpose highly Efficient System (HOLMES) CRISPR diagnostics is a rapid, sensitive, and cost-effective molecular diagnostic platform using CRISPR-Cas technology to detect specific nucleic acid sequences from pathogens or genetic targets. The system uses CRISPR-mediated cleavage and signal amplification to provide accurate results in roughly one hour. It delivers fast, affordable, and precise molecular diagnostics for disease detection, surveillance, and personalized healthcare.

The key product types of one-hour low-cost multipurpose highly efficient system (HOLMES) CRISPR diagnostics include kits, instruments, reagents, and other related products. Kits are ready-to-use sets containing all necessary materials and reagents for performing CRISPR-based diagnostic tests efficiently. These solutions are supported by services such as sample collection and preparation, assay development and validation, data interpretation and reporting, and quality control and assurance. They are applied in areas including infectious disease diagnosis, oncology, genetic disease screening, and other applications, with end users including hospitals and clinics, diagnostic laboratories, research institutes, and other organizations.

The one-hour low-cost multipurpose highly efficient system(HOLMES) clustered regularly interspaced short palindromic repeats (CRISPR) diagnostics market consists of revenues earned by entities by providing services such as rapid nucleic acid detection and analysis, molecular diagnostic testing, pathogen identification, genetic mutation screening, point-of-care diagnostic services, and clinical sample processing. The market value includes the value of related goods sold by the service provider or included within the service offering. The one-hour low-cost multipurpose highly efficient system (HOLMES) clustered regularly interspaced short palindromic repeats (CRISPR) diagnostics market also includes sales of assay consumables, reaction chambers and cartridges, and associated hardware and software components. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.